Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 13/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23327513 | 1.00 | TYK2 (0.45) | TYK2STAT3JAK1PDE4DPKM | |
| SCHEMBL23327190 | 0.89 | TYK2 (0.46) | TYK2STAT3PDE4DKDM4E | |
| SCHEMBL30548430 | 0.89 | TYK2 (0.46) | TYK2STAT3PDE4DKDM4E | |
| SCHEMBL23327715 | 0.83 | TYK2 (0.53) | TYK2PDE4D | |
| SCHEMBL23327211 | 0.79 | TYK2 (0.46) | TYK2STAT3JAK1PDE4DKDM4E | |
| SCHEMBL30548435 | 0.79 | TYK2 (0.46) | TYK2STAT3JAK1PDE4DKDM4E | |
| SCHEMBL23327406 | 0.79 | TYK2 (0.48) | TYK2JAK1PDE4D | |
| SCHEMBL30548451 | 0.78 | TYK2 (0.56) | TYK2STAT3JAK1PDE4D | |
| SCHEMBL23327701 | 0.78 | TYK2 (0.56) | TYK2STAT3JAK1PDE4D | |
| SCHEMBL23327534 | 0.78 | TYK2 (0.44) | TYK2JAK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | TYK2, JAK1, JAK2 | TYK2 1/4885STAT3 376/4885JAK1 2/4885 |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | TYK2 1/4885STAT3 76/4885JAK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.